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Wehave exploited a prandial insulin analog to elucidate the underlying structure and dynam-
ics of insulin as a monomer in solution. A model was provided by insulin lispro (the active
component of Humalog®; Eli Lilly and Co.). Whereas NMR-based modeling recapitulated
structural relationships of insulin crystals (T-state protomers), dynamic anomalies were
revealed by amide-proton exchange kinetics in D2O. Surprisingly, the majority of hydrogen
bonds observed in crystal structures are only transiently maintained in solution, includ-
ing key T-state-speciﬁc inter-chain contacts. Long-lived hydrogen bonds (as deﬁned by
global exchange kinetics) exist only at a subset of four α-helical sites (two per chain)
ﬂanking an internal disulﬁde bridge (cystine A20–B19); these sites map within the pro-
posed folding nucleus of proinsulin. The anomalous ﬂexibility of insulin otherwise spans
its active surface and may facilitate receptor binding. Because conformational ﬂuctuations
promote the degradation of pharmaceutical formulations, we envisage that “dynamic re-
engineering” of insulin may enable design of ultra-stable formulations for humanitarian use
in the developing world.
Keywords: diabetesmellitus,NMRspectroscopy, hydrogen bond, amide-proton exchange, protein structure, protein
dynamics, protein engineering, protein therapeutics
INTRODUCTION
We describe the structure and dynamics of a rapid-acting (pran-
dial) insulin analog based on 1H-NMR spectroscopy. Structure-
based design of such analogs has enhanced the safety and efﬁcacy
of glycemic control in the treatment of diabetes mellitus (DM;
Selden et al., 1986; Tripathi and Srivastava, 2006). The impor-
tance of tight control in Type 1 DM has been demonstrated by
clinical trials, including the landmark DCCT (The Diabetes Con-
trol Group and Complications Trial Research Group, 1993) and
its successor, the Epidemiology of Diabetes Interventions and
Complications Study (Nathan et al., 2005). Although the safety
of protocols to achieve tight control in long-established Type 2
DM may vary based on individual metabolic and clinical features
[e.g., transient excursions in blood glucose concentration, dura-
tion of disease, and co-morbidities (Saltiel, 2001)], the United
Kingdom Prospective Diabetes Study (Nicollerat, 2000) and sub-
group analysis in the recent Action to Control Cardiovascular Risk
in Diabetes Study (Riddle, 2010; Gerstein et al., 2011) support the
appropriateness of moderate glycemic targets (Ismail-Beigi et al.,
2011). To achieve these clinical objectives, rapid- and long-acting
insulin analogs have been designed based on classical crystal struc-
tures (Baker et al., 1988) and general physico-chemical principles
(Creighton, 1997).
To obtain a model monomer, our studies employed insulin
lispro (Ciszak et al., 1995; Campbell et al., 1996), the active
component of Humalog® (Eli Lilly and Co.); its sequence is
shown in Figure 1A. Approved by the United States Food and
Drug Administration in 1996 (Campbell et al., 1996; Holle-
man and Hoekstra, 1997) and currently in broad clinical use
(Hartman, 2008), this analog (also designated KP-insulin) con-
tains paired substitutions near the C-terminus of the B-chain
(ProB28 → Lys and LysB29 →Pro; asterisk in Figure 1A and black
spheres in Figure 1B). Interchange of residues B28 and B29,which
recapitulates a feature of insulin-like growth factor I, does not per-
turb the receptor-binding surface of the hormone (Baker et al.,
1988), and so the analog retains native potency (Shoelson et al.,
1992). Subtle perturbation of the dimer interface (Ciszak et al.,
1995) nonetheless leads to accelerated disassembly of the zinc
insulin analog hexamer on subcutaneous injection (DeFelippis
et al., 2001). Accordingly, the analog is absorbed into the blood-
stream more rapidly than is wild-type insulin (Bakaysa et al.,
1996). Although intrinsic rates of clearance from the bloodstream
are presumably unaffected, enhanced absorption also leads to
more rapid exhaustion of the subcutaneous depot and thus more
limited duration of action (DeFelippis et al., 2001). The struc-
tural basis of such altered pharmacokinetics (PK) and pharma-
codynamics (PD) has been investigated by X-ray crystallography
(Figure 2; Ciszak et al., 1995). Whereas the overall structure of
the variant hexamer closely resembles that of wild-type insulin
(Figures 2A,B), superposition of component dimers reveals splay-
ing of the C-terminal segments of the B-chain (box in Figure 2C)
with weakening of β-sheet-related hydrogen bonds (dotted lines;
Dodson et al., 1993; Ciszak et al., 1995). Such analysis high-
lighted the subtle contributions of ProB28 and LysB29 to the
wild-type dimer interface (Figure 2D). Structure-based design of
insulin lispro and related analog insulin aspart (AspB28-insulin,
the active component of Novolog®; Novo-Nordisk, Ltd.) repre-
sented pioneering examples of protein engineering in molecular
pharmacology (Brange et al., 1988, 1992a; DeFelippis et al., 2001).
1H-NMR spectroscopy in principle provides an opportunity to
probe the structure and dynamics of insulin as amonomer in solu-
tion and so complements crystallographic studies of insulin self-
assembly (Hua et al., 1991). Such spectroscopic studies were long
hampered by the complex self-association equilibria characteristic
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FIGURE 1 | Sequence and structure of insulin. (A) Sequence of human
insulin with A-chain at top (red) and B-chain beneath (blue). Cysteines are
highlighted in orange with linkages as indicated (bars). Sites of substitution
in KP-insulin are indicated (asterisks). (B) Ribbon model of insulin (T-state
protomer; Protein Databank accession code 4INS; Baker et al., 1988). The
A-chain is shown in red, and the B-chain in blue. Disulﬁde bridges are
indicated by gold spheres (sulfur atoms); pairings are shown in black boxes.
Black spheres indicate Cα carbons of residues B28 and B29 (site of
sequence interchange in KP-insulin). Selected side chains at the
receptor-binding surface are also shown as labeled.
of wild-type insulin at micromolar-to-millimolar protein con-
centrations (Weiss et al., 1991). In the present study we have
explored a broad range of conditions to enable rigorous 1H-NMR
characterization of insulin lispro in aqueous solution without
the need for additional amino-acid substitutions or addition of
organic co-solvents (Hua and Weiss, 1991). Whereas the solution
structure of monomeric insulin lispro closely resembles a crystal-
lographic T-state protomer (Figures 1B and 2C, right; Baker et al.,
1988), analysis of amide-proton exchange in D2O demonstrated
novel dynamic features. This technique focuses on the kinetics
of exchange between peptide N-1H protons by solvent-derived
deuterons as a measure of both global stability and site-speciﬁc
conformational ﬂuctuations (Wüthrich, 1986; Englander et al.,
1996). Remarkably, the majority of main-chain hydrogen-bonds
observed in the crystal structure of insulin are only transiently
maintained in solution: long-lived hydrogen bonds are restricted
to a subset of α-helical residues ﬂanking the A20–B19 disulﬁde
bridge. This pattern of core conformational stability and ﬂank-
ing ﬂuctuations is discussed in relation to mechanisms of receptor
FIGURE 2 | Design of insulin lispro. (A,B) Ribbon models of the wild-type
zinc insulin hexamer (A) and KP-insulin (B). The hexamer type is in each
caseT3R
f
3. The A- and B-chains in (A) are shown in light and dark gray,
respectively; the A- and B-chains in (B) are shown in red and blue. In each
hexamer the overlying positions of the axial zinc ions are shown as central
black circles coordinated by the side chains of HisB10 (three per metal-ion
binding site). Respective Protein Databank accession codes are 1TRZ
(wild-type) and 1LPH (KP-insulin; Ciszak et al., 1995). (C) Structure of
component TRf insulin dimer in the wild-type hexamer (light and dark gray)
and variant hexamer (red and blue). The structures were aligned according
to the main-chain atoms of residues B3–B28 and A2–A21. T- and
Rf-protomers are shown at right and left, respectively, in an orientation that
highlights the dimer-related β-sheet (residues B24–B28) and its four
inter-molecular hydrogen bonds (dotted lines; Baker et al., 1988). Boxed
region contains sites of substitution in KP-insulin. (D) Enlargement of boxed
region in (C). The KP substitutions are associated with lengthening of the
inter-molecular hydrogen bonds and subtle repositioning of residues
B28–B30 (Ciszak et al., 1995). Respective GlyB23 Cα atoms in corresponding
Rf protomers are indicated by gray (wild-type) and blue (variant) spheres. In
the wild-type hexamer electron density (accession code 1TRZ) was not well
deﬁned for the Cγ, Cδ, and Nε atoms of LysB29.
binding (De Meyts and Whittaker, 2002; Nakagawa et al., 2005)
and proinsulin folding (Steiner, 1967; Qiao et al., 2003; Weiss,
2009; Yang et al., 2010a).
Conformational stability and ﬂuctuations within insulin are
pertinent not only to in vivo biosynthesis and signaling, but also
to pharmaceutical formulation (Brange et al., 1987). Rates of
chemical and physical degradation, key determinants of shelf-life
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above room temperature, are enhancedby transient partial unfold-
ing processes (Brange and Langkjoer, 1993). Such degradation is
accelerated among rapid-acting insulin analogs, including insulin
lispro, and poses a particular challenge among indigent patients
in the developing world (Hua et al., 2008). Indeed, the same
structural perturbations introduced by substitutions at positions
B28 and/or B29 to achieve accelerated absorption lead at the
same time to compromised pharmaceutical stability. How may
this trade-off, seemingly intrinsic to the logic of protein design,
be avoided? The dynamic view of insulin provided herein by
1H-NMR analysis promises to provide an opportunity for the
“dynamic re-engineering” of favorable pharmacokinetic- and sta-
bility properties. We envisage that such second-generation analog
formulations would circumvent the cold chain of insulin delivery
and thereby facilitate their storage and use to address the emerging
global pandemic of DM (Osei, 2003; Lefebvre and Pierson, 2004).
MATERIALS AND METHODS
SYNTHESIS OF INSULIN ANALOGS
Human insulin and insulin lispro were obtained from Eli Lilly Co.
(Indianapolis, IN, USA). Synthetic analogs, kindly provided by
Prof. P. G. Katsoyannis and coworkers, were prepared as described
(Hu et al., 1993). Predicted molecular masses were in each case
veriﬁed by mass spectrometry.
CIRCULAR DICHROISM
Circular dichroism (CD) spectra were obtained as described (Hua
et al., 2001). Samples were dissolved in 10mM acetic acid (0.14%
v/v) at pH 3.0; the protein concentration was ca. 25μM. For equi-
librium denaturation studies, samples were diluted in the same
buffer to 5μM; guanidine-HCl was employed as denaturant (Hua
et al., 2002a, 2006c). Data were obtained at 25 or 37˚C and ﬁtted
by non-linear least squares to a two-state model (Sosnick et al.,
2000).
NMR SPECTROSCOPY
Spectra were obtained at 700MHz in 10mM deuterioacetic acid
(pH/pD 3.0; direct meter reading) at 25 and 37˚C (Hua et al.,
1996a); the protein concentration was ca. 0.5mM. Resonance
assignment was obtained by standard methods (Wüthrich, 1986).
Sites of hydrogen bonds were inferred from the pattern of amide-
protonprotection inD2O(Hua andWeiss,1990). Spectrawere also
acquired at pH 7.4 and in 20% (v/v) deuterioacetic acid (pH 2.0).
STRUCTURE CALCULATIONS
Distance-geometry/simulated annealing calculations (DG/SA)
were performed using program DG-II (Havel and Snow, 1991);
restrained molecular dynamics (RMD) were calculated using X-
PLOR (Brunger, 1992). Nuclear overhauser enhancement (NOE)-
related and dihedral-angle restraints were used for molecular
modeling as described (Hua et al., 1998).
AMIDE-PROTON EXCHANGE
1H–2H-exchange was monitored in 10mM deuterioacetic acid
(pD 3.0) at either 25 or 37˚C. The protocol is outlined in schematic
form in Figure S1 in Supplementary Material. Intrinsic hydrogen
exchange rates (k int) were estimated using the Sphere program (H.
Roder, Fox Chase Cancer Center, Philadelphia, PA, USA). Protec-
tion factors (PFs) are deﬁned as the ratio of intrinsic exchange
rate constants:observed exchange rate constants (k int/kobs; Eng-
lander et al., 1996). Sites of global exchange were identiﬁed on
the basis of comparative studies of protein analogs differing in
thermodynamic stability but otherwise similar in structure; at
such sites values of ΔGu derived from denaturation studies were
in accordance with values of ΔGHX predicted by global PFs
according to:
ΔGHX = −RT ln(kint/kobs) = −RT ln(PF) (1)
whereR is theRydberg constant,andT is the absolute temperature.
Values of kobs and PF are provided in Table S1 in Supplementary
Material.
RESULTS
Twenty years ago protein engineering enabled the application of
2D 1H-NMR methods to insulin (Weiss et al., 1991). Simulta-
neous substitutions were introduced at successive self-association
surfaces (such as the classical B28-related dimer contact and B10-
related trimer contact; Figures 2A–C) to achieve the millimolar
protein concentrations then required for 2D 1H-NMR study (Hua
et al., 1996a). Advances in 1H-NMR instrumentation (partic-
ularly development of ultra-high sensitivity cryogenic probes)
presently enable such study at protein concentrations as low as
0.1–0.5mM. Aided by this technology, we have found that KP-
insulin is tractable in the absence of ancillary substitutions at
the trimer interface, providing an opportunity to characterize a
prandial insulin in clinical use.
SOLUTION STRUCTURE
Representative 1D 1H-NMR spectra of KP-insulin under diverse
solution conditions are shown in Figure 3; these include aqueous
solution at pH 7.4 (pertinent to conditions in the bloodstream)
and at pH 3.0 (optimal for analysis of amide-proton exchange).
In each case KP-insulin exhibits patterns of chemical shifts, reso-
nance line widths, and NOEs consistent with an isolated monomer
(Hua et al., 1996a). Short- and medium-range NOEs character-
istic of secondary structure were in each case consistent with
the classical T state (Figure S2 in Supplementary Material). The
set of inter-residue NOEs was found to be similar to that pre-
viously observed in 2D 1H-NMR studies of AspB10-KP-insulin
(also designated DKP-insulin; Hua et al., 1996a). Structural mod-
els were calculated by DG/RMD based on 803 distance restraints,
47 dihedral-angular restraints, and 31 hydrogen-bond restraints
(Table S2 in Supplementary Material); a total of 881 restraints (ca.
17.3 restraints per residue) were thus employed. As expected, the
resulting ensemble of structures (Figure 4B) closely resembles a
collection of crystallographic T-state protomers (Figure 4A).
Distance-geometry/RMDensembles of KP-insulin exhibit pep-
tide segments of varying precision and so are evocative of dynamic
variability. The C-terminal residues of the B-chain (residues B25–
B30) are lesswell deﬁned in solution than among crystal structures,
presumably due to stabilizing effects of self-assembly (Baker et al.,
1988). Conversely, positioning of the N-terminal arm of the B-
chain in solution (residues B1–B4) is more precisely deﬁned than
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FIGURE 3 | 1H-NMR spectra of KP-insulin at 700MHz. Spectra were
obtained under a variety of solution conditions: (A) aqueous solution at pH
7.4 and 32˚C, (B) 20% (v/v) deuterioacetic acid (pH 2.0) at 32˚C, (C) 10mM
deuterioacetic acid (pH 3.0) at 32˚C, and (D) 10mM deuterioacetic acid (pH
3.0) at 25˚C. In each panel the amide-aromatic spectrum in H2O is shown at
left, and the aliphatic spectrum in D2O is shown at right.
would be expected based on the diversity of crystallographic con-
formations (Figures 4A,B). The latter difference may reﬂect the
DG/RMD protocol (which enforced all restraints simultaneously
and so may underestimate conformational ﬂuctuations), or con-
versely, variable positioning of the arm in crystals may be enjoined
by lattice contacts (Baker et al., 1988). Because DG/RMD ensem-
bles do not directly provide dynamic information, we sought an
independent probe of protein stability and dynamics. 1H-NMR
analysis of amide-proton exchange in D2O in principle provides
such a probe (Wüthrich andWagner, 1979; Englander et al., 1996).
AMIDE-PROTON EXCHANGE
The amide proton (HN) within each peptide-bond unit is labile,
i.e., able to exchange with a solvent-derived 1H or 2H (Englan-
der et al., 1996). The rate of such exchange is typically measured
under EX2 conditions wherein the observed rate constant (kobs)
is the product of a pH-dependent intrinsic rate constant (k int)
and the site-speciﬁc opening rate constant (kop; Bai et al., 1993).
The extent to which kobs differs from k int enables calculation of
individual PFs, deﬁned as k int/kobs (Roder et al., 1985). PF values
depend on local structural environment and so deﬁne a residue-
speciﬁc probe. In small globular proteins non-negligible PFs are
ordinarily restricted to sites of hydrogen bonding. Protection
FIGURE 4 | NMR-derived structure of KP-insulin. (A) Reference
collection of crystallographic T-state protomers (stereo pair). The structures
(wild-type accession codes 1MSO, 4INS, 1APH, 1BPH, 1CPH, 1DPH, 1TRZ,
1TYL, 1TYM, 2INS, 1ZNI, 1LPH, 1G7A; KP-insulin accession code 2JMN)
were aligned according to the main-chains within α-helices (residues A2–A7,
A13–A19, and B9–B19). The A-chains are shown in red and B-chains in blue.
(B) DG/RMD-derived ensemble of structures of KP-insulin as a monomer in
solution. The color code and alignment scheme are as in (A).
within KP-insulin might therefore be expected at HN sites within
α-helices (A3–A8, A15–A19, and B12–B19, excluding N-terminal
residues), within β-turns (B7–B10 and B20–B23), or participating
in inter-chain hydrogen bonds; dimer-speciﬁc protection would
not be expected within the isolated B-chain β-strand (B24–B28;
Figure 2C). The extent of protection at a given site depends on
rates of structural ﬂuctuations leading to hydrogen-bond break-
age and exposure to solvent. Two limiting cases are of interest: (i)
local stability is sufﬁciently marked that exchange requires global
unfolding and (ii) local ﬂuctuations are sufﬁciently marked that
protection is negligible even in the presence of a non-random
mean structure.
1H–2H-exchange in KP-insulin is illustrated in Figure 5 (1D
spectra) and Figure 6 (2D spectra). The studies were conducted at
pD 3.0 and 25˚C to optimize the quality of the 1H-NMR spec-
trum in a pH regime between the extremes of acid and base
catalysis. The majority of amide protons were found to exchange
within 5min, and so their resonances were not observed in the
initial spectrum. Rates of exchange were thus measurable only for
a minority of amide resonances. These reside within or adjoin-
ing α-helices (Figure 5B) and at inter-chain hydrogen bonds A11
HN · · ·O = C B4 and B6 HN · · ·O = C A6 (vertical dashed lines
in Figure 5A). Resonance overlap among amide resonances in α-
helices was resolved in successive TOCSY spectra (Figure 6). A
broad range of PFs was observed (Figure 7A; Table S1 in Sup-
plementary Material), suggesting uncorrelated and inequivalent
segmental ﬂuctuations. Whereas the central B-chain α-helix and
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C-terminal A-chain α-helix contain sites of marked protection,
exchange was rapid within the A1–A8 α-helix and the two B-chain
β-turns. A summary of sites of observable protection is provided
in Figure 7B in relation to hydrogen bonds as deﬁned in crystal
structures and as inferred from DG/RMD models.
FIGURE 5 | One-dimensional 1H-NMR studies of amide-proton
exchange in D2O (pH 3.0 and 25˚C). (A) Spectra of downﬁeld amide
region as observed after successive times in D2O. Vertical dashed lines
indicate the amide protons of CysA11 (9.86 ppm; left) and LeuB6 (9.17 ppm;
center), which are engaged in T-state-speciﬁc inter-chain hydrogen bonds
(see text). (B) Spectra of major amide region at corresponding times;
selected assignments are as indicated at top. The two sharp downﬁeld
resonances between 8.6 and 8.7 ppm belong to the Hε ring resonances of
HisB5 and HisB10; the sharp resonance at 8.3 ppm is an impurity.
DYNAMIC CLASSIFICATION
Protection factors may be interpreted in relation to protein sta-
bility (at sites of global exchange) or protein dynamics (at sites of
subglobal or local exchange; Roder et al., 1985). Global refers to an
overall equilibrium between native and unfolded structures; such
exchange implies that local or segmental conformational ﬂuctua-
tions either do not involve the breakage of hydrogen bonds or do
not enable their exposure to solvent. Subglobal pertains to coop-
erative segmental ﬂuctuations whereas local refers to uncorrelated
local motions leading to hydrogen-bond breakage and exposure.
The thermodynamic stability of a protein imposes an upper bound
on observable PFs; intrinsic (random-coil) exchange rates impose
a lower bound.
To distinguish between these modes of exchange, the global
thermodynamic stability of KP-insulin was probed by chemical
denaturation (Figure S3 in Supplementary Material). Coopera-
tive unfolding at successive concentrations of guanidine-HCl was
observed by CD at a helix-sensitive wavelength (222 nm). Applica-
tion of a two-state model (N⇔U) enabled an estimate of the free
energy of unfolding (ΔGu) to be obtained as extrapolated to zero
denaturant concentration (Hua et al., 2002a). The resulting esti-
mate (3.3± 0.1 kcal/mol; see Table 1) implies a PF ceiling between
250 and 300. Because the 1H-NMR studies were conducted in
D2O, comparative CD-detected studies in H2O and D2O were
undertaken (each in 10mM acetic acid at pH/pD 3.0); the results
suggested that solvent isotope effects on stability are negligible
(Figure S4 in Supplementary Material).
Four sites of global exchange were identiﬁed as depicted in
Figure 8A. Their identiﬁcation was based on PFs at or near the
stability ceiling as imposed by ΔGu: LeuA16 and TyrA19 (the C-
terminal segment of the second A-chain α-helix) and TyrB16 and
ValB18 (the C-terminal segment of the central B-chain α-helix).
Global stability as estimated based on the average of the PFs at
these sites (ΔGHX 3.26± 0.03 kcal/mol) is in accordance with
FIGURE 6 |Two-dimensional 1H-NMR studies of amide-proton exchange
in D2O (pH 3.0 and 25˚C). (A) Baseline TOCSY spectrum in H2O. Selected
HN–Hα cross-peak assignments are as follows: (a) LeuA16, (b) TyrA19, (c) TyrB16,
and (d) ValB18. (B–D)TOCSY spectra as acquired at successive times after
dissolution in D2O: (B) 2h, (C) 14h, and (D) 48h. Assignments are as
indicated.
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FIGURE 7 | Summary of protection factors (PF) and survey of hydrogen
bonds. (A) Plot of residue-speciﬁc PFs in KP-insulin (vertical axis) versus
sequence (horizontal axis). Color code: (red circles) sites of global
exchange, (purple) subglobal exchange, and (green) local ﬂuctuations. (B)
Summary of amide hydrogen bonds (vertical segments) as inferred from
NMR studies (top) and as predicted by crystal structures (bottom). The color
code is as in (A). Sites of global exchange in the A- and B-chains cluster
near cystine A20–B19.
Table 1 | Estimates of global thermodynamic stabilitya.
Analog Temp (˚C) ΔGu ΔGHX
KP-insulinb 25 3.3±0.1 3.26±0.03
TrpA13-KP-insulin 25 2.7±0.1 2.73±0.03
KP-insulin 37 2.6±0.1 2.51±0.03
AspB10-KP-insulinb 37 3.0±0.1 3.11±0.01
aIndependent estimates of thermodynamic stability (given in kcal/mol) were
inferred from CD-detected guanidine denaturation studies (column 3) and NMR-
detected 1H–2H-exchange (column 4). CD assays were performed in 10mM
acetic acid (pH 3.0); NMR studies were performed in 10mM deuterioacetic acid
(pD 3.0).
bKP-insulin, an analog containing IGF-I-related substitutions ProB28 →Lys and
LysB29 →Pro (Ciszak et al., 1995). AspB10-KP-insulin (also designated DKP-insulin)
contains the additional substitutionHisB10 →Asp as originally described in amono-
genic syndrome of diabetesmellitus and hyperproinsulinemia (Carroll et al., 1988).
AspB10 enhances binding to the insulin receptor andType I IGF-receptor (Schwartz
et al., 1987; Hansen et al., 2011); its clinical use has been precluded on the basis of
increasedmitogenicity (Milazzo et al., 1997) and potential carcinogenicity (Hansen
et al., 2011). Whereas the KP switch impairs stability, AspB10 enhances stability
(Kaarsholm et al., 1993).
the results of chemical denaturation (ΔGu 3.3± 0.1 kcal/mol;
Table 1). Similar consistency was observed at 37˚C wherein KP-
insulin exhibits both reduced stability to chemical denaturation
(ΔGu 2.6± 0.1 kcal/mol) and proportionately accelerated global
FIGURE 8 | Structural map of amide-proton exchange. (A) Sites of
global exchange are shown in relation to a ribbon model of theT state:
residues A16, A19, B16, and B18 cluster near cystine A20–B19 (box). (B)
Corresponding ribbon model showing sites of subglobal exchange: residues
A15, A17, A18, A20, B12, B14, B15, B17, and B19. (C) Sites of local
exchange: residues A3, A9–A12, A14, B6, B11, B13, and B20. (D) Sites for
which HN resonances were not observed in D2O, presumably due to rapid
exchange (i.e., within 5min). Color bars at top in (A–C) indicate range of PFs
shown relative to the maximum value set by global stability; normalized
protection factors are given in Table S1 in Supplementary Material. Asterisk
in (D) highlights lack of protection within the A1–A8 α-helix; ValA3 exhibits
slight protection [arrowhead in (C)].
exchange (ΔGHX 2.51± 0.03 kcal/mol; Table 1). These sites of
global exchange kinetics ﬂank internal cystine A20–B19; their
nascent folding is proposed to stabilize the folding nucleus of
proinsulin (see Discussion; Hua et al., 2006a). To verify their
global status, comparative amide-proton exchange studies were
undertaken of analogs of KP-insulin of lower or greater ther-
modynamic stability (TrpA13-KP-insulin and AspB10-KP-insulin;
Table 1); surface substitutions were chosen to avoid perturbations
within the hydrophobic core. Whereas substitution HisB10 →Asp
provides a more favorable C-cap to the B-chain α-helix (Weiss
et al., 1990), substitution LeuA13 →Trp would be expected to
introduce a destabilizing “reverse hydrophobic effect” (Chu et al.,
1992) and potentially perturb the long-range packing of PheB1.
These modiﬁcations were each associated with commensurate
changes inΔGHX andΔGu in accordancewith the global exchange
model. Representative 1H-NMR data are respectively provided in
Figures S5 and S6 in Supplementary Material.
Sites of subglobal exchange were identiﬁed as depicted in
Figure 8B. Such sites (heuristically deﬁned by PF values between
100 and200;Table S1 in SupplementaryMaterial) adjoin the global
sites in the A-chain α-helix (residues A15, A17, A18, and A20) and
B-chain α-helix (residues B12, B14, B15, B17, and B19). Sites of
local exchange (3<PFs< 30) were likewise identiﬁed as depicted
in Figure 8C. These sites were observed in the A-chain at residues
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A3,A9–A11,A13, andA14; and in the B-chain at B6, B11, B13, and
B20. Structural correlates are as follows. (i) Protection is negligible
or absent within the A1–A8 α-helix; only ValA3 HN was observed
in D2O (PFA3 3.6± 0.2). Such rapid exchange stands in contrast
to retention of canonical helix-related NOEs in this segment (see
above; Figure S2 in Supplementary Material). (ii) β-Turn probes
LeuB11 (hydrogen bonded to the carbonyl oxygen of GlyB8) and
GlyB20 (hydrogen bonded to the carbonyl oxygen of B23) exhibit
PFs between 10 and 20 (PFB11 11.4± 0.4 and PFB20 19.0± 0.6).
(iii) Inter-chain hydrogen bonds (A11 HN · · ·O = C B4 and B6
HN · · ·O = C A6) are likewise transient (PFA11 14.5± 0.5 and
PFB6 4.3± 0.3). No PFs were observed with values between 30 and
100, providing a clear empirical demarcation between segments
exhibiting subglobal ﬂuctuations and sites of local exchange.
No protection was observed at the remaining sites (Figure 8D),
themajority of which are uninvolved in hydrogen bonding in crys-
tal structures (Baker et al., 1988). Conspicuous by their absence,
however, is lack of observable HN protection at six sites of
hydrogen-bonds characteristic of the classical 2-Zn (T6) insulin
hexamer. These map both within the A-chain (A20 HN · · ·O = C
A17) and B-chain (B22 HN · · ·O = C B19 and B23 HN · · ·O = C
B20). Accelerated 1H–2H-exchange within the central B-chain β-
turn correlates with enhanced crystallographic thermal B-factors
at residues B20–B23 (Baker et al., 1988).Anomalous lack of protec-
tion was also observed at sites of inter-chain hydrogen bonds (A20
HN · · ·O = C B23, B4 HN · · ·O = C A11, and B25 HN · · ·O = C
A19). Because the latter two inter-chain hydrogen bonds are bro-
ken in the crystallographic TR transition (Baker et al., 1988), such
allosteric reorganization may exploit intrinsic sites of ﬂexibility
in an insulin protomer as originally envisaged by Hodgkin and
colleagues (Chothia et al., 1983).
DISCUSSION
The zinc insulin hexamer exhibits representative structural fea-
tures of globular proteins in general, including canonical elements
of secondary structure, well-organized hydrophobic core, ligand-
binding sites, and capacity for allosteric reorganization (Chothia
et al., 1983). A model critical to the development and applica-
tion of X-ray crystallographic techniques (Baker et al., 1988), the
hexamer provides a stable storage formof the hormone both in the
secretory granules of pancreatic β-cells (Steiner, 1967;Dodson and
Steiner, 1998) and in pharmaceutical formulations (Brange et al.,
1987). Structure-based mutagenesis of the zinc insulin hexamer
(Brange et al., 1988) enabled development of rapid-acting insulin
analog formulations for prandial injection and use in pumps (Zin-
man et al., 1997). Although originally described as “monomeric”
(Brange et al., 1988), such analogs are formulated as zinc insulin
hexamers (Humalog®and Novolog®; DeFelippis et al., 2001) or
as an equilibrium distribution of zinc-free oligomers (Apidra®;
Garg et al., 2005). The overall goal of such protein engineering
is enhanced glycemic control with reduced risk of major hypo-
glycemic events per decrement in hemoglobin A1c (Melki et al.,
1998; Renner et al., 1999; Hartemann-Heurtier et al., 2003).
The present study has exploited a rapid-acting analog in cur-
rent clinical use as a biophysical model of the insulin monomer.
Insulin lispro contains paired substitutions near the C-terminus
of the B-chain [ProB28 → Lys and LysB29 →Pro; (Bakaysa et al.,
1996)]. These changes are peripheral to the receptor-binding sur-
face (Shoelson et al., 1992) and so are compatiblewith native hypo-
glycemic potency (Campbell et al., 1996). Although dimerization
is markedly impaired in the absence of zinc ions, zinc-dependent
hexamer assembly (critical to the stability of its pharmaceutical
formulation) ismaintained on binding of phenolic ligands (Ciszak
et al., 1995). The structure anddynamics of the zinc-freemonomer
are of broad interest in relation to receptor-binding in vivo (Dod-
son and Steiner, 1998) and mechanisms of degradation in vitro
(Brange and Langkjoer, 1993). Structural relationships within
and between A- and B-chains are also pertinent to the folding of
proinsulin (as a nascent monomer in the endoplasmic reticulum;
Dodson and Steiner, 1998) and its aggregation-coupledmisfolding
in a newly recognized monogenic diabetes syndrome (Stoy et al.,
2007; Weiss, 2009).
The solution structure of insulin lispro closely resembles the
crystallographic T state as observed within structures of zinc
insulin dimers and hexamers (Baker et al., 1988). This result was
expected in light of previous NMR studies of related and unrelated
engineered insulin monomers under a variety of solution condi-
tions by several laboratories (for review, see Baker et al., 1988;
De Meyts and Whittaker, 2002). Characterization of insulin lispro
as a native-like monomer at pH 3.0 and in the absence of an
organic co-solvent nonetheless provided an opportunity to obtain
a quantitative assessment of amide-proton exchange in D2O. Use
of an acidic pH facilitates observation of 1H–2H-exchange in ﬂex-
ible systems due to reduction in baseline rates of exchange from
the random-coil state; between pH 3.0 and 4.0 the simultaneous
efﬁciency of acid-catalyzed and base-catalyzed exchange was thus
minimized (Roder et al., 1985; Wüthrich, 1986; Englander et al.,
1996). In addition, the absence of an organic co-solvent permit-
ted application of tabulated random-coil exchange rate constants
(Englander et al., 1996) and hence calculation of site-speciﬁc PFs
in the native state (Bai et al., 1993; Englander et al., 1996). Strik-
ingly, at the majority of potential sites protection could not be
observed, due either to absence of hydrogen bonding or local con-
formational ﬂuctuations. Evidence for the latter is provided by
the conspicuous absence of observable protection at sites oth-
erwise structurally compatible with hydrogen-bond formation in
the majority of DG/RMD models (e.g.,A20 HN · · ·O = CA17 and
A21 HN · · ·O = C B23; see Results). Because insulin is more stable
under acidic conditions than at neutral pH (due to protonation of
HisB5; Bryant et al., 1993), the present results may underestimate
the extent of conformational ﬂuctuations in the bloodstream.
From the present analysis three structural classes of hydro-
gen bonds may be deﬁned: (i) those within stable α-helices,
(ii) those within β-turns, or (iii) those between the A- and B-
chains. Surprisingly, the majority of such hydrogen bonds are
labile in solution (i.e., exhibit PFs smaller than would be pre-
dicted based on the global thermodynamic stability of the pro-
tein) irrespective of structural class. Global exchange kinetics
was observed only at four sites (two per chain) ﬂanking inter-
nal cystine A20–B19 (Figure 8A). Successive classes of exchange
kinetics provide a dynamic map (Figures 8B–D). The lability of
the majority of hydrogen bonds in monomeric insulin stands
in contrast to the greater PFs observed in pioneering studies of
bovine pancreatic trypsin inhibitor (Wagner and Wüthrich, 1986;
www.frontiersin.org October 2011 | Volume 2 | Article 48 | 7
Hua et al. Dynamics of insulin
Roder,1989). Previous studies have suggested that hydrogenbonds
within insulin are stabilized on self-assembly (Hua et al., 1993) in
accordance with high-resolution crystal structures (Baker et al.,
1988).
Sites of global exchange kinetics in KP-insulin coincide with
the proposed folding nucleus of proinsulin (Hua et al., 2006b).
Although the latter precursor comprises a single polypeptide
chain, the success of insulin chain combination (Katsoyannis,
1966) implies that chemical information required for folding is
containedwithin the sequences of theA- andB domains (Tang and
Tsou,1990;Wang andTsou,1991). Studies of the disulﬁde-coupled
folding of proinsulin and related polypeptides – foreshortened
single-chain analogs (mini-proinsulin; Huang et al., 2001) and
insulin-like growth factors – are notable for populated one- and
two-disulﬁde intermediates (Hober et al., 1992; Miller et al., 1993;
Qiao et al., 2001). Such intermediates are thought to acquire struc-
ture stepwise on successive disulﬁde pairing (for reviews see Jia
et al., 2003; Weiss, 2009; Hua, 2010).
Spectroscopic studies of equilibrium peptide models support a
structural pathway of disulﬁde pairing. In this process a key role
is played by preferred initial formation of cystine A20–B19. In the
native state this internal bridge connects the C-terminal α-helix of
the A domain to the central α-helix of the B domain, connecting
sites of global exchange kinetics as deﬁned in the present study
(Hua et al., 1995, 2002a,b). Although studies of proinsulin itself
have been limited by aggregation (imposing a requirement for
pH conditions >9), the disulﬁde pathways of mini-proinsulin and
IGF-I are well characterized near neutral pH (Hober et al., 1992,
1994; Miller et al., 1993; Qiao et al., 2001). In such studies cystine
A20–B19 is the only one-disulﬁde species to accumulate (Mil-
ner et al., 1999). We therefore envisage that the dynamic “core”
of KP-insulin in its native state reﬂects its role in folding (Hua
et al., 1996b, 2001). Impaired folding of the A20–B19-associated
folding nucleus may account for the proteotoxicity and β-cell dys-
function caused by GlyB23 →Val and related B-domain mutations
in patients with permanent neonatal-onset neonatal DM (Weiss,
2009).
Sites of rapid, local, and subglobal exchange are prominent
within the N-terminal segments of the A- and B-chains. Only
limited protection was observed, for example, at the sites of key
T-state-speciﬁc inter-chain hydrogen bonds (A11 HN · · ·O = C
B4 and B6 HN · · ·O = C A6); no protection was observed cor-
responding to B4 HN · · ·O = C A11. Breakage of such contacts
(a prominent feature of the TR transition among zinc hexamers;
Chothia et al., 1983) has been proposed to accompany binding of
insulin to the insulin receptor (Baker et al., 1988; Nakagawa et al.,
2005). Although co-crystal structures of the hormone-receptor
complex have not been determined, evidence for such induced ﬁt
in the B-chain has been obtained through characterization of sub-
stitutions of GlyB8. Formation of the A11 HN · · ·O = C B4 and B6
HN · · ·O = CA6hydrogen bonds is coupled tomaintenance of the
adjoining T-state-speciﬁc β-turn (residues B7–B10). Remarkably,
stabilization (or destabilization) of this turn by respective d- (or
l) amino-acid substitutions at GlyB8 is associated with reciprocal
effects on activity. On the one hand, because in the T state GlyB8
exhibits a negative φ dihedral angle, characteristic of d-amino
acids, diverse d-substitutions at B8 are compatible with native-like
structure but low activity (Nakagawa et al., 2005;Hua et al., 2006c).
On the other hand,l-amino-acid substitutions, consistentwith the
positive B8 φ angle of GlyB8 in the R state, can exhibit high activ-
ities despite markedly impaired stability and low yields of chain
combination or yeast expression (Kristensen et al., 1997;Guo et al.,
2005; Hua et al., 2006c). Accordingly, we have proposed that GlyB8
functions an “ambidextrous switch” between folding-competent
(T-like) and active (R-like) conformations. In this model nascent
T-like local structure in the proximal arm (including inter-domain
hydrogen bonding and contacts by the imidazole ring of HisB5;
Hua et al., 2006c) enhance the efﬁciency and ﬁdelity of disulﬁde
pairing. The present 1H–2H-exchange data highlight the ﬂexibil-
ity of T-like structure in the B-chain and hence its amenability for
structural reorganization on receptor binding.
The ﬂexibility of insulin may also contribute to its suscepti-
bility to degradation. Whereas zinc hexamer assembly permits
pharmaceutical formulation of adequate shelf life, degradation
at elevated temperatures complicates the transport, storage, and
use of insulin in the developing world. Brange and colleagues
have characterized two modes of degradation, chemical processes
leading to changes in covalent structure (such as formation of
iso-aspartic acid or disulﬁde-liked polymers; Brange et al., 1992b)
andphysical processes leading to aggregation-coupleddenaturation
and ﬁbrillation (Brange et al., 1997). Conformational ﬂuctuations
enhance rates of both chemical and physical degradation. The
transient nature of the majority of hydrogen bonds in an insulin
monomer is thus likely to play a central role in such mechanisms.
In this regard the anomalous dynamic properties of the A2–A8 α-
helix (as manifest by rapid amide-proton exchange and attenuated
13Cα/β chemical shifts despite maintenance of helix-related NOE
patterns) represent an“Achilles’Heel”(Yang et al., 2010b).We spec-
ulate the molecular repair of this nascent helix may permit design
of second-generation insulin analogs that are refractory to ther-
mal degradation and so of humanitarian value in the developing
world. One step in this direction has been taken based on solid-
state NMR studies of insulin ﬁbrils and analysis of β-branched
side chains (Yang et al., 2010b). An alternative route toward sta-
bilization of this segment may be provided by its tethering to the
B-chain through the engineering of active single-chain analogs
(Hua et al., 2008; Rajpal et al., 2009).
Following submission of this article, a complementary analy-
sis of hydrogen bonds in insulin was presented (Antolíková et al.,
2011). Remarkably, this and the present studies have put forward
a similar perspective based on unrelated biophysical methodolo-
gies. Employing isothermalmicrocalorimetry,Brzozowski, Jirácek,
and their respective colleagues exploited N-methylated insulin
analogs to distinguish between the roles of inter- and intra-
molecular hydrogen bonds at the dimer interface. Of particular
interest, formation (or disruption) of the intra-molecular B25
HN · · ·O = C A19 hydrogen bond (unprotected in insulin lispro)
was observed to correlate with the relative competency of the
B-chain to form inter-molecular β-sheet-related hydrogen bonds
(Antolíková et al., 2011)). Such coupling, supported by crystallo-
graphic analyses of variant zinc hexamers, highlights the non-local
nature of a hydrogen-bond network and its potential functional
relevance. The particular N-methylated insulin analogs studied
by Antolíková et al. (2011) exemplify the power of chemical
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modiﬁcation to dissect speciﬁc dynamic features of a globular
protein.
CONCLUSION
In the present study we have presented the solution structure of a
prandial insulin analog as a monomer in solution. Dynamic char-
acterization by amide-proton exchange has provided surprising
insights into the lability of hydrogen bonds within and between
the insulin chains. Although these hydrogen bonds are promi-
nent features of classical crystal structures (Baker et al., 1988) and
contribute to self-assembly (Dodson et al., 1993), their breakage is
likely to contribute to the biological activity of the hormone as well
as its degradation in pharmaceutical formulations. To our knowl-
edge, this report represents the ﬁrst quantitative analysis of 1H–2H
PFs in an insulin analog. We envisage that a deeper understanding
of the dynamics of insulin will enable design of second-generation
analogs with application to the developing world.
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